. "Pacientky s karcinomem prsu men\u0161\u00ED nebo rovno 1 cm jsou sice st\u00E1le vz\u00E1cn\u00E9, ale v d\u016Fsledku funguj\u00EDc\u00EDho mam\u00E1rn\u00EDho screeningu jejich po\u010Det roste. Vhodn\u00E1 adjuvantn\u00ED l\u00E9\u010Dba u t\u011Bchto pacientek je v dne\u0161n\u00ED dob\u011B opakovan\u011B \u010Dasto diskutov\u00E1na s ohledem na riziko relapsu onemocn\u011Bn\u00ED. V klinick\u00FDch studi\u00EDch je zastoupen\u00ED velmi mal\u00FDch n\u00E1dor\u016F m\u00E9n\u011B \u010Dast\u00E9 a samotn\u00E1 klinick\u00E1 studie na adjuvantn\u00ED l\u00E9\u010Dbu velmi mal\u00FDch n\u00E1dor\u016F se nepl\u00E1nuje. Bli\u017E\u0161\u00ED retrospektivn\u00ED anal\u00FDza studi\u00ED, kter\u00E9 maj\u00ED v mal\u00E9m po\u010Dtu zahrnuty i velmi mal\u00E9 n\u00E1dory, ukazuje na hor\u0161\u00ED progn\u00F3zu t\u011Bchto pacientek v p\u0159\u00EDpad\u011B p\u0159\u00EDtomnosti pozitivity HER2. Nep\u0159\u00EDmo lze tedy usuzovat na vhodnost adjuvantn\u00ED l\u00E9\u010Dby s p\u0159\u00EDtomnost\u00ED trastuzumabu i u takto mal\u00FDch n\u00E1dor\u016F prsu. Rozhodnut\u00ED v\u0161ak mus\u00ED b\u00FDt individu\u00E1ln\u00ED s ohledem na ostatn\u00ED rizika onemocn\u011Bn\u00ED a rizika samotn\u00E9 l\u00E9\u010Dby pro danou pacientku. \u010Cl\u00E1nek je sp\u00ED\u0161e \u00FAvahou k vyvol\u00E1n\u00ED diskuze na toto provokativn\u00ED t\u00E9ma."@cs . . "RIV/00216224:14110/10:00051833" . "Very Small Breast Cancer, HER2 Positive, and Trastuzumab in Adjuvant Treatment"@en . "breast cancer; very small tumors; trastuzumab; adjuvant treatment"@en . "CZ - \u010Cesk\u00E1 republika" . "14110" . . . "Breast cancer patients with a tumor size of 1 cm are still rare but their number is increasing as a consequence of mammary screening. It is logical that the best adjuvant treatment in such cancers is often discussed with respect to the risk of relapse of the disease. The number of patients in clinical trials with very small breast cancer is quite low, and a specific clinical trial for such patients is not planned. Retrospective analysis of some clinical trials which included patients with breast cancer and with very small size shows the worse prognosis of patients with HER2 positive tumors. Indirectly, we can assume the application of adjuvant treatment with trastuzumab in such very small breast cancer. However, the decision should be individual with regards to further risk factors for the disease and risk of the treatment itself. This article is more a contemplation in order to provoke discussion on this provocative subject."@en . . "Vyzula, Rostislav" . . "[07B1D5766C53]" . "23" . "1"^^ . . "Velmi mal\u00E9 karcinomy prsu, HER2-pozitivn\u00ED a l\u00E9\u010Dba trastuzumabem v adjuvanci"@cs . "Velmi mal\u00E9 karcinomy prsu, HER2-pozitivn\u00ED a l\u00E9\u010Dba trastuzumabem v adjuvanci" . "Velmi mal\u00E9 karcinomy prsu, HER2-pozitivn\u00ED a l\u00E9\u010Dba trastuzumabem v adjuvanci" . "Velmi mal\u00E9 karcinomy prsu, HER2-pozitivn\u00ED a l\u00E9\u010Dba trastuzumabem v adjuvanci"@cs . "295462" . "1" . "1"^^ . . "Very Small Breast Cancer, HER2 Positive, and Trastuzumab in Adjuvant Treatment"@en . "RIV/00216224:14110/10:00051833!RIV12-MSM-14110___" . . "I" . . . "Pacientky s karcinomem prsu men\u0161\u00ED nebo rovno 1 cm jsou sice st\u00E1le vz\u00E1cn\u00E9, ale v d\u016Fsledku funguj\u00EDc\u00EDho mam\u00E1rn\u00EDho screeningu jejich po\u010Det roste. Vhodn\u00E1 adjuvantn\u00ED l\u00E9\u010Dba u t\u011Bchto pacientek je v dne\u0161n\u00ED dob\u011B opakovan\u011B \u010Dasto diskutov\u00E1na s ohledem na riziko relapsu onemocn\u011Bn\u00ED. V klinick\u00FDch studi\u00EDch je zastoupen\u00ED velmi mal\u00FDch n\u00E1dor\u016F m\u00E9n\u011B \u010Dast\u00E9 a samotn\u00E1 klinick\u00E1 studie na adjuvantn\u00ED l\u00E9\u010Dbu velmi mal\u00FDch n\u00E1dor\u016F se nepl\u00E1nuje. Bli\u017E\u0161\u00ED retrospektivn\u00ED anal\u00FDza studi\u00ED, kter\u00E9 maj\u00ED v mal\u00E9m po\u010Dtu zahrnuty i velmi mal\u00E9 n\u00E1dory, ukazuje na hor\u0161\u00ED progn\u00F3zu t\u011Bchto pacientek v p\u0159\u00EDpad\u011B p\u0159\u00EDtomnosti pozitivity HER2. Nep\u0159\u00EDmo lze tedy usuzovat na vhodnost adjuvantn\u00ED l\u00E9\u010Dby s p\u0159\u00EDtomnost\u00ED trastuzumabu i u takto mal\u00FDch n\u00E1dor\u016F prsu. Rozhodnut\u00ED v\u0161ak mus\u00ED b\u00FDt individu\u00E1ln\u00ED s ohledem na ostatn\u00ED rizika onemocn\u011Bn\u00ED a rizika samotn\u00E9 l\u00E9\u010Dby pro danou pacientku. \u010Cl\u00E1nek je sp\u00ED\u0161e \u00FAvahou k vyvol\u00E1n\u00ED diskuze na toto provokativn\u00ED t\u00E9ma." . . . "4"^^ . "0862-495X" . "Klinick\u00E1 onkologie" . . .